This study evaluates bone mineral density (BMD) and trabecular bone score (TBS) in relationship with new markers of chronic kidney disease (CKD), fibroblast growth factor 23 (FGF23), and klotho. The patients in this cross-sectional study were divided as follows: group A -patients in stages G1-3; group B -patients in stages G4 - 5 according to KDIGO. Plasma levels of soluble klotho and FGF23 were determined by ELISA. Bone mineral density (BMD) and trabecular bone score (TBS) were measured. 74 patients with CKD (mean age 68.8 years) were included in the study. Higher levels of FGF23 were observed in group B (N=15) compared to group A (N=59; p=0.001) were observed. FGF23 was higher in group A compared to group B. Significant difference in TBS within the first 3 stages of CKD was observed (mean TBS in G1=1.375 vs. G2=1.340 vs. G3a=1.24; p<0.05) and negative correlation of FGF23 and TBS (R=-0.33; p=0.05) and positive correlation between klotho and TBS (R=0.419; p=0.04) was observed. This study confirmed that FGF23 and klotho are associated with TBS, but TBS reflects a decrease in kidney function only in the first 3 stages of CKD. Thus, FGF23 and klotho together with TBS are promising markers of early trabecular bone impairment in CKD.

5th Department of Internal Medicine University Hospital Bratislava Bratislava Slovakia

Zobrazit více v PubMed

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl: S1–130.2009 PubMed

ALEKSOVA J, KURNIAWAN S, ELDER GJ. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos Int. 2018;29:1447–1455. doi: 10.1007/s00198-018-4468-y. PubMed DOI

ALEM AM, SHERRARD DJ, GILLEN DL, WEISS NS, BERESFORD SA, HECKBERT SR, WONG C, STEHMAN-BREEN C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–399. doi: 10.1046/j.1523-1755.2000.00178.x. PubMed DOI

AVIN KG, MOORTHI RN. Bone is not alone: the effects of skeletal muscle dysfunction in chronic kidney disease. Curr Osteoporos Rep. 2015;13:173–179. doi: 10.1007/s11914-015-0261-4. PubMed DOI PMC

BEZERRA De CARVALHO KS, VASCO RFV, CUSTODIO MR, JORGETTI V, MOYSÉS RMA, ELIAS RM. Chronic kidney disease is associated with low BMD at the hip but not at the spine. Osteoporos Int. 2019;30:1015–1023. PubMed

BRUNEROVA L, RONOVA P, VERESOVA J, BERANOVA P, POTOEKOVA J, KASALICKY P, RYCHLIK I. Osteoporosis and impaired trabecular bone score in hemodialysis patients. Kidney Blood Press Res. 2016;41:345–354. doi: 10.1159/000443439. PubMed DOI

CARNEY EF. The impact of chronic kidney disease on global health. Nature Reviews Nephrology. 2020;16:251–251. doi: 10.1038/s41581-020-0268-7. PubMed DOI

IIMORI S, MORI Y, AKITA W, KUYAMA T, TAKADA S, ASAI T, KUWAHARA M, SASAKI S, TSUKAMOTO Y. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant. 2012;27:345–351. doi: 10.1093/ndt/gfr317. PubMed DOI

ISAKOVA T, NICKOLAS TL, DENBURG M, YARLAGADDA S, WEINER DE, GUTIÉRREZ OM, BANSAL V, ROSAS SE, NIGWEKAR S, YEE J, KRAMER H. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Am J Kidney Dis. 2017;70:737–751. doi: 10.1053/j.ajkd.2017.07.019. PubMed DOI

JACKULIAK P, KUŽMA M, KILLINGER Z, PAYER J. Good long-term glycemic compensation is associated with better trabecular bone score in postmenopausal women with type 2 diabetes. Physiol Res. 2019;68:S149–S156. doi: 10.33549/physiolres.934304. PubMed DOI

KLAWANSKY S, KOMAROFF E, CAVANAUGH PF, JR, MITCHELL DY, GORDON MJ, CONNELLY JE, ROSS SD. Relationship between age, renal function and bone mineral density in the US population. Osteoporosis International. 2003;14:570–576. doi: 10.1007/s00198-003-1435-y. PubMed DOI

KOMABA H. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD] (Article in Japanese) Clin Calcium. 2010;20:1028–1036. PubMed

KURO-O M. The FGF23 and Klotho system beyond mineral metabolism. Clin Exp Nephrol. 2017;21:64–69. doi: 10.1007/s10157-016-1357-6. PubMed DOI

KUŽMA M, VAŇUGA P, SÁGOVÁ I, PÁVAI D, JACKULIAK P, KILLINGER Z, BINKLEY NC, WINZENRIETH R, GENANT HK, PAYER J. Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol. 2019;180:201–211. doi: 10.1530/EJE-18-0881. PubMed DOI

McCLOSKEY EV, ODÉN A, HARVEY NC, LESLIE WD, HANS D, JOHANSSON H, BARKMANN R, BOUTROY S, BROWN J, CHAPURLAT R, ELDERS PJ, FUJITA Y, GLÜER C-C, GOLTZMAN D, IKI M, KARLSSON M, KINDMARK A, KOTOWICZ M, KURUMATANI N, KWOK T, LAMY O, LEUNG J, LIPPUNER K, LJUNGGREN Ö, LORENTZON M, MELLSTRÖM D, MERLIJN T, OEI L, OHLSSON C, PASCO JA, RIVADENEIRA F, ROSENGREN B, SORNAY-RENDU E, SZULC P, TAMAKI J, KANIS JA. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Mineral Res. 2016;31:940–948. doi: 10.1002/jbmr.2734. PubMed DOI

MUÑOZ-CASTAÑEDA JR, RODELO-HAAD C. Klotho/FGF23 and Wnt signaling as important players in the comorbidities associated with chronic kidney disease. Toxins. 2020;12:185. doi: 10.3390/toxins12030185. PubMed DOI PMC

MUÑOZ-TORRES M, MANZANARES CÓR, DOVA R, GARCÍA-MARTÍN A, AVILÉS-PÉREZ MD, NIETO SERRANO R, ANDÚJAR-VERA F, GARCÍA-FONTANA B. Usefulness of trabecular bone score (TBS) to identify bone fragility in patients with primary hyperparathyroidism. J Clin Densitom. 2019;22:162–170. doi: 10.1016/j.jocd.2018.06.005. PubMed DOI

NAYLOR KL, McARTHUR E, LESLIE WD, FRASER LA, JAMAL SA, CADARETTE SM, POUGET JG, LOK CE, HODSMAN AB, ADACHI JD, GARG AX. The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014;86:810–818. doi: 10.1038/ki.2013.547. PubMed DOI

NAYLOR KL, PRIOR J, GARG AX, BERGER C, LANGSETMO L, ADACHI JD, GOLTZMAN D, KOVACS CS, JOSSE RG, LESLIE WD. Trabecular bone score and incident fragility fracture risk in adults with reduced kidney function. Clin J Am Soc Nephrol. 2016;11:2032–2040. doi: 10.2215/CJN.00720116. PubMed DOI PMC

NICKOLAS TL, McMAHON DJ, SHANE E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17:3223–3232. doi: 10.1681/ASN.2005111194. PubMed DOI

PIMENTEL A, URENA-TORRES P, ZILLIKENS MC, BOVER J, COHEN-SOLAL M. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017;92:1343–1355. doi: 10.1016/j.kint.2017.07.021. PubMed DOI

RAMPERSAD C, WHITLOCK RH, LESLIE WD, RIGATTO C, KOMENDA P, BOHM C, HANS D, TANGRI N. Trabecular bone score in patients with chronic kidney disease. Osteoporos Int. 2020;31:1905–1912. doi: 10.1007/s00198-020-05458-1. PubMed DOI

RODELO-HAAD C, SANTAMARIA R, MUNOZ-CASTANEDA JR, PENDON-RUIZ DE MIER MV, MARTIN-MALO A, RODRIGUEZ M. FGF23, Biomarker or target? Toxins (Basel) 2019;11 doi: 10.3390/toxins11030175. PubMed DOI PMC

RUPP T, BUTSCHEIDT S, VETTORAZZI E, OHEIM R, BARVENCIK F, AMLING M, ROLVIEN T. High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis. Osteoporos Int. 2019;30:1655–1662. doi: 10.1007/s00198-019-04996-7. PubMed DOI

SANDRU F, CARSOTE M, DUMITRASCU MC, ALBU SE, VALEA A. Glucocorticoids and trabecular bone score. J Med Life. 2020;13:449–453. PubMed PMC

WEISINGER JR, BELLORIN-FONT E. Outcomes associated with hypogonadism in women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11:361–370. doi: 10.1053/j.ackd.2004.07.009. PubMed DOI

WEST SL, LOK CE, LANGSETMO L, CHEUNG AM, SZABO E, PEARCE D, FUSARO M, WALD R, WEINSTEIN J, JAMAL SA. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30:913–919. doi: 10.1002/jbmr.2406. PubMed DOI

YAVROPOULOU MP, VAIOS V, PIKILIDOU M, CHRYSSOGONIDIS I, SACHINIDOU M, TOURNIS S, MAKRIS K, KOTSA K, DANIILIDIS M, HARITANTI A, LIAKOPOULOS V. Bone quality assessment as measured by trabecular bone score in patients with end-stage renal disease on dialysis. J Clin Densitom. 2017;20:490–497. doi: 10.1016/j.jocd.2016.11.002. PubMed DOI

YENCHEK RH, IX JH, SHLIPAK MG, BAUER DC, RIANON NJ, KRITCHEVSKY SB, HARRIS TB, NEWMAN AB, CAULEY JA, FRIED LF. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7:1130–1136. doi: 10.2215/CJN.12871211. PubMed DOI PMC

YOON HE, KIM Y, SHIN SJ, HONG YS, KANG KY. Factors associated with low trabecular bone scores in patients with end-stage kidney disease. J Bone Miner Metab. 2019;37:475–483. doi: 10.1007/s00774-018-0938-8. PubMed DOI

ZOU D, WU W, HE Y, MA S, GAO J. The role of klotho in chronic kidney disease. BMC Nephrol. 2018;19:285. doi: 10.1186/s12882-018-1094-z. PubMed DOI PMC